Clinical Trials Directory

Trials / Completed

CompletedNCT00852592

Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
46 (actual)
Sponsor
Northwestern University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to understand the efficacy of light therapy for bipolar depression.

Detailed description

Bipolar Disorders (BD) are associated with chronic depression, disability, and increased suicide risk. Building on earlier findings, we conducted a 6-week randomized, double-blind, placebo-controlled trial to investigate the efficacy of midday light therapy for bipolar depression. The aims were to examine the change in depression levels and the proportion of patients who responded and remitted. We assessed predictors of response with measures of side effects, sleep quality, suicidality, and psychosocial functioning. We included depressed adults with BD-Type I or II confirmed on the SCID interview and taking stable-dosed antimanic medication. We excluded patients with psychosis, rapid cycling, obsessive compulsive disorder, alcohol or substance use disorders, hypomania or mania, and severe suicidality. Patients were randomized to 7000 lux broad spectrum light therapy OR 50 lux dim red light for 45-60 minutes daily. Weekly, the blinded-clinician assessed symptoms with the Structured Interview Guide for the Hamilton Depression Scale with Atypical Depression Supplement (SIGH-ADS) and global functioning.

Conditions

Interventions

TypeNameDescription
DEVICE7000lux broad-spectrum lightdosage - 15-60minutes NOON-2PM daily
DEVICE50lux dim red lightdosage: 15-60minutes NOON-2PM daily

Timeline

Start date
2009-05-01
Primary completion
2014-12-01
Completion
2015-02-01
First posted
2009-02-27
Last updated
2016-11-07
Results posted
2016-11-07

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00852592. Inclusion in this directory is not an endorsement.